|
1
|
Hu S, Lu H, Xie W, Wang D, Shan Z, Xing X,
Wang XM, Fang J, Dong W, Dai W, et al: TDO2+ myofibroblasts mediate
immune suppression in malignant transformation of squamous cell
carcinoma. J Clin Invest. 132:e1576492022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leemans CR, Braakhuis BJ and Brakenhoff
RH: The molecular biology of head and neck cancer. Nat Rev Cancer.
11:9–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sequeira I, Neves JF, Carrero D, Peng Q,
Palasz N, Liakath-Ali K, Lord GM, Morgan PR, Lombardi G and Watt
FM: Immunomodulatory role of Keratin 76 in oral and gastric cancer.
Nat Commun. 9:34372018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pouyssegur J, Dayan F and Mazure NM:
Hypoxia signalling in cancer and approaches to enforce tumour
regression. Nature. 441:437–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen Z, Han F, Du Y, Shi H and Zhou W:
Hypoxic microenvironment in cancer: Molecular mechanisms and
therapeutic interventions. Signal Transduct Target Ther. 8:702023.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bhandari V, Hoey C, Liu LY, Lalonde E, Ray
J, Livingstone J, Lesurf R, Shiah YJ, Vujcic T, Huang X, et al:
Molecular landmarks of tumor hypoxia across cancer types. Nat
Genet. 51:308–318. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abu El Maaty MA, Terzic J, Keime C, Rovito
D, Lutzing R, Yanushko D, Parisotto M, Grelet E, Namer IJ, Lindner
V, et al: Hypoxia-mediated stabilization of HIF1A in prostatic
intraepithelial neoplasia promotes cell plasticity and malignant
progression. Sci Adv. 8:eabo22952022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beasley NJ, Leek R, Alam M, Turley H, Cox
GJ, Gatter K, Millard P, Fuggle S and Harris AL: Hypoxia-inducible
factors HIF-1alpha and HIF-2alpha in head and neck cancer:
Relationship to tumor biology and treatment outcome in surgically
resected patients. Cancer Res. 62:2493–2497. 2002.PubMed/NCBI
|
|
9
|
Duan Y, Zhou M, Ye B, Yue K, Qiao F, Wang
Y, Lai Q, Wu Y, Cao J, Wu Y, et al: Hypoxia-induced miR-5100
promotes exosome-mediated activation of cancer-associated
fibroblasts and metastasis of head and neck squamous cell
carcinoma. Cell Death Dis. 15:2152024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bao MH and Wong CC: Hypoxia, metabolic
reprogramming, and drug resistance in liver cancer. Cells.
10:17152021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang R, Chen H, Xing L, Wang B, Hu M, Ou
X, Chen H, Deng Y, Liu D, Jiang R and Chen J: Hypoxia-induced
circWSB1 promotes breast cancer progression through destabilizing
p53 by interacting with USP10. Mol Cancer. 21:882022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rey-Keim S and Schito L: Origins and
molecular effects of hypoxia in cancer. Semin Cancer Biol. 106–107.
166–178. 2024.PubMed/NCBI
|
|
13
|
Jing X, Yang F, Shao C, Wei K, Xie M, Shen
H and Shu Y: Role of hypoxia in cancer therapy by regulating the
tumor microenvironment. Mol Cancer. 18:1572019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ong CT and Corces VG: Enhancer function:
New insights into the regulation of tissue-specific gene
expression. Nat Rev Genet. 12:283–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zabidi MA, Arnold CD, Schernhuber K,
Pagani M, Rath M, Frank O and Stark A: Enhancer-core-promoter
specificity separates developmental and housekeeping gene
regulation. Nature. 518:556–559. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang M, Chen Q, Wang S, Xie H, Liu J,
Huang R, Xiang Y, Jiang Y, Tian D and Bian E: Super-enhancers
complexes zoom in transcription in cancer. J Exp Clin Cancer Res.
42:1832023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang Y, Jiang YY and Lin DC:
Super-enhancer-mediated core regulatory circuitry in human cancer.
Comput Struct Biotechnol J. 19:2790–2795. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang YY, Lin DC, Mayakonda A, Hazawa M,
Ding LW, Chien WW, Xu L, Chen Y, Xiao JF, Senapedis W, et al:
Targeting super-enhancer-associated oncogenes in oesophageal
squamous cell carcinoma. Gut. 66:1358–1368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang F, Yang Z, Tan Y and Li Y:
Super-enhancer function and its application in cancer targeted
therapy. NPJ Precis Oncol. 4:22020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao Q, Yang L, Lu M, Jin R, Ye H and Ma T:
The artificial intelligence and machine learning in lung cancer
immunotherapy. J Hematol Oncol. 16:552023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Swanson K, Wu E, Zhang A, Alizadeh AA and
Zou J: From patterns to patients: Advances in clinical machine
learning for cancer diagnosis, prognosis, and treatment. Cell.
186:1772–1791. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kourou K, Exarchos TP, Exarchos KP,
Karamouzis MV and Fotiadis DI: Machine learning applications in
cancer prognosis and prediction. Comput Struct Biotechnol J.
13:8–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Boehm KM, Khosravi P, Vanguri R, Gao J and
Shah SP: Harnessing multimodal data integration to advance
precision oncology. Nat Rev Cancer. 22:114–126. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Issa NT, Stathias V, Schürer S and
Dakshanamurthy S: Machine and deep learning approaches for cancer
drug repurposing. Semin Cancer Biol. 68:132–142. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu H, Zhang W, Zhang Y, Adegboro AA,
Fasoranti DO, Dai L, Pan Z, Liu H, Xiong Y, Li W, et al: Mime: A
flexible machine-learning framework to construct and visualize
models for clinical characteristics prediction and feature
selection. Comput Struct Biotechnol J. 23:2798–2810. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chu Y, Dai E, Li Y, Han G, Pei G, Ingram
DR, Thakkar K, Qin JJ, Dang M, Le X, et al: Pan-cancer T cell atlas
links a cellular stress response state to immunotherapy resistance.
Nat Med. 29:1550–1562. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Quah HS, Cao EY, Suteja L, Li CH, Leong
HS, Chong FT, Gupta S, Arcinas C, Ouyang JF, Ang V, et al: Single
cell analysis in head and neck cancer reveals potential immune
evasion mechanisms during early metastasis. Nat Commun.
14:16802023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bill R, Wirapati P, Messemaker M, Roh W,
Zitti B, Duval F, Kiss M, Park JC, Saal TM, Hoelzl J, et al:
CXCL9:SPP1 macrophage polarity identifies a network of cellular
programs that control human cancers. Science. 381:515–524. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wichmann G, Rosolowski M, Krohn K, Kreuz
M, Boehm A, Reiche A, Scharrer U, Halama D, Bertolini J, Bauer U,
et al: The role of HPV RNA transcription, immune response-related
gene expression and disruptive TP53 mutations in diagnostic and
prognostic profiling of head and neck cancer. Int J Cancer.
137:2846–2457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saito T, Asai S, Tanaka N, Nohata N,
Minemura C, Koma A, Kikkawa N, Kasamatsu A, Hanazawa T, Uzawa K and
Seki N: Genome-Wide super-enhancer-based analysis: Identification
of prognostic genes in oral squamous cell carcinoma. Int J Mol Sci.
23:91542022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Meng X, Lou QY, Yang WY, Wang YR, Chen R,
Wang L, Xu T and Zhang L: The role of non-coding RNAs in drug
resistance of oral squamous cell carcinoma and therapeutic
potential. Cancer Commun (Lond). 41:981–1006. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu Q, You L, Nepovimova E, Heger Z, Wu W,
Kuca K and Adam V: Hypoxia-inducible factors: Master regulators of
hypoxic tumor immune escape. J Hematol Oncol. 15:772022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nasri D, Manwar R, Kaushik A, Er EE and
Avanaki K: Photoacoustic imaging for investigating tumor hypoxia: A
strategic assessment. Theranostics. 13:3346–3367. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Balamurugan K: HIF-1 at the crossroads of
hypoxia, inflammation, and cancer. Int J Cancer. 138:1058–1066.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kopecka J, Salaroglio IC, Perez-Ruiz E,
Sarmento-Ribeiro AB, Saponara S, De Las Rivas J and Riganti C:
Hypoxia as a driver of resistance to immunotherapy. Drug Resist
Updat. 59:1007872021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roma-Rodrigues C, Mendes R, Baptista PV
and Fernandes AR: Targeting tumor microenvironment for cancer
therapy. Int J Mol Sci. 20:8402019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang W, Han Y, Jo HA, Lee J and Song YS:
Non-coding RNAs shuttled via exosomes reshape the hypoxic tumor
microenvironment. J Hematol Oncol. 13:672020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mao XG, Xue XY, Lv R, Ji A, Shi TY, Chen
XY, Jiang XF and Zhang X: CEBPD is a master transcriptional factor
for hypoxia regulated proteins in glioblastoma and augments hypoxia
induced invasion through extracellular matrix-integrin mediated
EGFR/PI3K pathway. Cell Death Dis. 14:2692023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ma S, Zhao Y, Lee WC, Ong LT, Lee PL,
Jiang Z, Oguz G, Niu Z, Liu M, Goh JY, et al: Hypoxia induces
HIF1α-dependent epigenetic vulnerability in triple negative breast
cancer to confer immune effector dysfunction and resistance to
anti-PD-1 immunotherapy. Nat Commun. 13:41182022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim S, Park S, Moon EH, Kim GJ and Choi J:
Hypoxia disrupt tight junctions and promote metastasis of oral
squamous cell carcinoma via loss of par3. Cancer Cell Int.
23:792023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Abe Y, Mukudai Y, Kurihara M, Houri A,
Chikuda J, Yaso A, Kato K, Shimane T and Shirota T: Tumor protein
D52 is upregulated in oral squamous carcinoma cells under hypoxia
in a hypoxia-inducible-factor-independent manner and is involved in
cell death resistance. Cell Biosci. 11:1222021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schito L and Semenza GL: Hypoxia-inducible
factors: Master regulators of cancer progression. Trends Cancer.
2:758–770. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lin YT and Wu KJ: Epigenetic regulation of
epithelial-mesenchymal transition: Focusing on hypoxia and TGF-beta
signaling. J Biomed Sci. 27:392020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Calo E and Wysocka J: Modification of
enhancer chromatin: What, how, and why? Mol Cell. 49:825–837. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Driskell OJ, Mironov A, Allan VJ and
Woodman PG: Dynein is required for receptor sorting and the
morphogenesis of early endosomes. Nat Cell Biol. 9:113–120. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Merdes A, Ramyar K, Vechio JD and
Cleveland DW: A complex of NuMA and cytoplasmic dynein is essential
for mitotic spindle assembly. Cell. 87:447–458. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Roossien DH, Miller KE and Gallo G:
Ciliobrevins as tools for studying dynein motor function. Front
Cell Neurosci. 9:2522015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ramos RL, De Heredia MMB, Zhang Y, Stout
RF, Tindi JO, Wu L, Schwartz GJ, Botbol YM, Sidoli S, Poojari A, et
al: Patient-specific mutation of Dync1h1 in mice causes brain and
behavioral deficits. Neurobiol Dis. 199:1065942024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pan H, Chai W, Liu X, Yu T, Sun L and Yan
M: DYNC1H1 regulates NSCLC cell growth and metastasis by
IFN-gamma-JAK-STAT signaling and is associated with an aberrant
immune response. Exp Cell Res. 409:1128972021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ling L, Wen Y, Chen H, Xiong Y, Liu X,
Chen J, Liu T and Zhang B: miR-134-3p driven by anisomycin impairs
ovarian cancer stem cell activity through inhibiting GPR137
expression. J Cancer. 14:3404–3415. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Palaniappan A, Ramar K and Ramalingam S:
Computational identification of novel stage-specific biomarkers in
colorectal cancer progression. PLoS One. 11:e01566652016.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wu ZH, Zhou T and Sun HY: DNA
methylation-based diagnostic and prognostic biomarkers of
nasopharyngeal carcinoma patients. Medicine (Baltimore).
99:e206822020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zheng Z, Wan Q, Liu J, Zhu H, Chu X and Du
Q: Evidence for dynein and astral microtubule-mediated cortical
release and transport of Gαi/LGN/NuMA complex in mitotic cells. Mol
Biol Cell. 24:901–913. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gazon H, Barbeau B, Mesnard JM and
Peloponese JM Jr: Hijacking of the AP-1 signaling pathway during
development of ATL. Front Microbiol. 8:26862018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Carthy JM, Sundqvist A, Heldin A, van Dam
H, Kletsas D, Heldin CH and Moustakas A: Tamoxifen inhibits
TGF-β-mediated activation of myofibroblasts by blocking non-smad
signaling through ERK1/2. J Cell Physiol. 230:3084–3092. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Rampioni Vinciguerra GL, Capece M,
Scafetta G, Rentsch S, Vecchione A, Lovat F and Croce CM: Role of
Fra-2 in cancer. Cell Death Differ. 31:136–149. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wu L, Wu W, Zhang J, Zhao Z, Li L, Zhu M,
Wu M, Wu F, Zhou F, Du Y, et al: Natural coevolution of tumor and
immunoenvironment in glioblastoma. Cancer Discov. 12:2820–2837.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gupta S, Kumar P, Kaur H, Sharma N, Saluja
D, Bharti AC and Das BC: Selective participation of c-Jun with
Fra-2/c-Fos promotes aggressive tumor phenotypes and poor prognosis
in tongue cancer. Sci Rep. 5:168112015. View Article : Google Scholar : PubMed/NCBI
|
